Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spero Therapeutics, Inc. - Common Stock
(NQ:
SPRO
)
2.110
+0.090 (+4.46%)
Streaming Delayed Price
Updated: 11:19 AM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Spero Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
These stocks that are showing activity before the opening bell on Thursday.
↗
June 18, 2026
Via
Chartmill
Top movers in Wednesday's session
↗
June 17, 2026
Via
Chartmill
Spero Therapeutics Inc (NASDAQ:SPRO) Reports Q4 Earnings Beat and Positive Regulatory Step
↗
March 26, 2026
Via
Chartmill
Topics
Earnings
Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat
↗
November 13, 2025
Spero Therapeutics (SPRO) smashed Q3 2025 earnings, with revenue of $5.44M beating $0 estimates and a narrower EPS loss of -$0.13.
Via
Chartmill
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
Insights Ahead: Spero Therapeutics's Quarterly Earnings
↗
November 12, 2025
Via
Benzinga
Earnings Outlook For Spero Therapeutics
↗
August 11, 2025
Via
Benzinga
An Overview of Spero Therapeutics's Earnings
↗
May 12, 2025
Via
Benzinga
A Glimpse of Spero Therapeutics's Earnings Potential
↗
March 26, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 12, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
August 12, 2025
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline
↗
August 12, 2025
SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy.
Via
Chartmill
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
↗
June 09, 2025
Via
Benzinga
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
↗
January 30, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Spero Therapeutics
↗
December 20, 2024
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
↗
May 31, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 30, 2025
Via
Benzinga
Unusual volume stocks in Friday's session
↗
May 30, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
May 29, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 28, 2025
Via
Benzinga
These stocks are making the most noise in today's session.
↗
May 28, 2025
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 28, 2025
Via
Benzinga
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
↗
May 28, 2025
Via
Benzinga
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
↗
May 28, 2025
GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
Via
Benzinga
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
↗
May 28, 2025
Via
Benzinga
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
↗
May 28, 2025
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 28, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
Earnings Scheduled For March 27, 2025
↗
March 27, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
